Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 478 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05201404RecruitingPhase 3
Namodenoson for advanced liver cancer with moderate cirrhosis
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Dallas, TexasAges 18 years+ - NCT05375370Recruiting
Testing a blood test to predict liver cancer coming back
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
RouenAges 18 years+ - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT06789198RecruitingPhase 1
Peptide vaccine for fibrolamellar liver cancer
This trial tests a patient-specific vaccine for people who have a rare type of liver cancer called fibrolamellar hepatocellular carcinoma (FL-HCC), or another cancer with the same genetic change. The vaccine is given after the cancer has been completely removed or treated, and it aims to teach your immune system to recognize and destroy any cancer cells that might be left.
TübingenAges 12 years+ - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT03253536Recruiting
Quality of life study after precise liver radiation
This study follows people with liver cancer (hepatocellular carcinoma) to see how their quality of life changes after a focused form of radiation called stereotactic ablative radiation therapy. It does not appear to test a new drug—rather, it measures patient-reported well-being after treatment.
Munich, BavariaAges 18 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT04745403RecruitingPhase 1
Trial of redirected HBV-targeting T cells for liver cancer
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
SingaporeAges 21–75 - NCT06236568Recruiting
Liver transplant study for liver cancer patients
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Modena, MOAges 18 years+ - NCT06389422RecruitingPhase 2
Radiation plus Keytruda for liver cancer with vein clots
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–90 - NCT06622031Recruiting
TIPS with lenvatinib and immunotherapy for advanced liver cancer
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Beijing, None SelectedAges 18–75 - NCT03612726Recruiting
Study for people with unresectable liver cancer
This trial looks at overall survival (how long people live) in real-world patients with unresectable liver cancer. It may help researchers understand outcomes outside of tightly controlled studies.
BeijingAges 18 years+ - NCT06904183RecruitingPhase 2
Study of lenvatinib, sintilimab, and DEB-TACE with or without HAIC for large liver cancer with portal vein tumor thrombus
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
Guangzhou, GuangdongAges 18–75 - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT06742424RecruitingPhase 2
PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Chengdu, SichuanAges 18–75 - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT05476432RecruitingPhase 3
One-day versus two-day chemotherapy for unresectable liver cancer
This study compares two schedules of chemotherapy to treat liver cancer that cannot be removed with surgery. It aims to see whether the shorter schedule works about as well, with similar safety.
Foshan, GuangdongAges 18–75 - NCT07806292RecruitingPhase 2
Combination therapy for inoperable liver cancer
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
Guangzhou, GuangdongAges 18–75 - NCT07594340RecruitingPhase 3
Advanced Liver Cancer Treatment Comparison Study
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06905262Recruiting
Finding cancer targets for liver cancer immunotherapy
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
NaplesAges 18–100
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 478 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.